Agenus BOT+BAL Combination Posts 48% Three-Year Survival in Recurrent Ovarian Cancer

The Quick Take

• Agenus reports 48% estimated three-year overall survival with its BOT+BAL combination therapy in recurrent ovarian cancer at IGCS 2026, with survival stable between years two and three
• Data is from a heavily pretreated population with a median of four prior therapy lines; nearly 75% of patients had platinum-resistant or refractory disease
• The durable benefit signal at three years in platinum-resistant ovarian cancer represents a clinically meaningful outcome against a historically high-unmet-need backdrop

Agenus Inc. (Nasdaq: AGEN) has presented three-year survival data for its BOT+BAL immuno-oncology combination at the International Gynecological Cancer Society 2026 meeting, reporting a 48% estimated overall survival rate in patients with recurrent ovarian cancer. Notably, the survival estimate held flat between years two and three, suggesting the combination may be producing durable long-term benefit rather than a survival tail that drops sharply after initial responders. The patient population is particularly difficult to treat: median prior therapy lines of four and nearly three-quarters of patients classified as platinum-resistant or refractory, the segment with the poorest historical outcomes in ovarian cancer.

The 48% three-year survival rate in platinum-resistant recurrent ovarian cancer would represent a clinically meaningful advance over current standard-of-care outcomes, where median overall survival in this population typically ranges from 12-15 months. If confirmed in a randomized trial, BOT+BAL would compete with late-line immuno-oncology options from larger players including AstraZeneca Imfinzi combination and Pfizer PARP inhibitor maintenance therapy. Agenus small-cap market capitalization relative to the commercial potential of an approved late-line ovarian cancer indication creates a significant asymmetric upside thesis for the BOT+BAL program, contingent on confirmatory data.

The forward signal is whether Agenus reports a planned Phase 3 trial design or regulatory submission pathway for BOT+BAL following these IGCS results. The FDA PDUFA date for any IND or BLA for BOT+BAL in ovarian cancer would be the next definitive catalyst. The macro variable is the competitive landscape: AstraZeneca, GSK, and Pfizer each have late-line ovarian cancer programs, and any major Phase 3 readout from a competitor in platinum-resistant disease could reframe the commercial opportunity or raise the bar for BOT+BAL regulatory success.

Synthesized from 1 source.